Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 24

1.

The development of novel LTA4H modulators to selectively target LTB4 generation.

Low CM, Akthar S, Patel DF, Löser S, Wong CT, Jackson PL, Blalock JE, Hare SA, Lloyd CM, Snelgrove RJ.

Sci Rep. 2017 Mar 17;7:44449. doi: 10.1038/srep44449.

2.

Resveratrol: How Much Wine Do You Have to Drink to Stay Healthy?

Weiskirchen S, Weiskirchen R.

Adv Nutr. 2016 Jul 15;7(4):706-18. doi: 10.3945/an.115.011627. Print 2016 Jul. Review.

PMID:
27422505
3.

Bufexamac ameliorates LPS-induced acute lung injury in mice by targeting LTA4H.

Xiao Q, Dong N, Yao X, Wu D, Lu Y, Mao F, Zhu J, Li J, Huang J, Chen A, Huang L, Wang X, Yang G, He G, Xu Y, Lu W.

Sci Rep. 2016 Apr 29;6:25298. doi: 10.1038/srep25298.

4.

Palladium-Catalyzed Benzylic Arylation of Pyridylmethyl Silyl Ethers: One-Pot Synthesis of Aryl(pyridyl)methanols.

Rivero AR, Kim BS, Walsh PJ.

Org Lett. 2016 Apr 1;18(7):1590-3. doi: 10.1021/acs.orglett.6b00450. Epub 2016 Mar 23.

5.

Evolutionary Limitation and Opportunities for Developing tRNA Synthetase Inhibitors with 5-Binding-Mode Classification.

Fang P, Guo M.

Life (Basel). 2015 Dec 8;5(4):1703-25. doi: 10.3390/life5041703. Review.

6.

Understanding the foundations of the structural similarities between marketed drugs and endogenous human metabolites.

O'Hagan S, Kell DB.

Front Pharmacol. 2015 May 13;6:105. doi: 10.3389/fphar.2015.00105. eCollection 2015.

7.

A fluorescent approach for identifying P2X1 ligands.

Ruepp MD, Brozik JA, de Esch IJ, Farndale RW, Murrell-Lagnado RD, Thompson AJ.

Neuropharmacology. 2015 Nov;98:13-21. doi: 10.1016/j.neuropharm.2015.05.016. Epub 2015 May 28.

8.

Modeling of human M1 aminopeptidases for in silico screening of potential Plasmodium falciparum alanine aminopeptidase (PfA-M1) specific inhibitors.

Sahi S, Rai S, Chaudhary M, Nain V.

Bioinformation. 2014 Aug 30;10(8):518-25. doi: 10.6026/97320630010518. eCollection 2014.

9.

Role of leukotriene A4 hydrolase aminopeptidase in the pathogenesis of emphysema.

Paige M, Wang K, Burdick M, Park S, Cha J, Jeffery E, Sherman N, Shim YM.

J Immunol. 2014 Jun 1;192(11):5059-68. doi: 10.4049/jimmunol.1400452. Epub 2014 Apr 25.

10.

Cytidine derivatives as IspF inhibitors of Burkolderia pseudomallei.

Zhang Z, Jakkaraju S, Blain J, Gogol K, Zhao L, Hartley RC, Karlsson CA, Staker BL, Edwards TE, Stewart LJ, Myler PJ, Clare M, Begley DW, Horn JR, Hagen TJ.

Bioorg Med Chem Lett. 2013 Dec 15;23(24):6860-3. doi: 10.1016/j.bmcl.2013.09.101. Epub 2013 Oct 8.

11.

Transcriptional and functional regulation of the intestinal peptide transporter PEPT1.

Spanier B.

J Physiol. 2014 Mar 1;592(5):871-9. doi: 10.1113/jphysiol.2013.258889. Epub 2013 Aug 19. Review.

12.

Structural origins for the loss of catalytic activities of bifunctional human LTA4H revealed through molecular dynamics simulations.

Thangapandian S, John S, Lazar P, Choi S, Lee KW.

PLoS One. 2012;7(7):e41063. doi: 10.1371/journal.pone.0041063. Epub 2012 Jul 25.

13.

Molecular dynamics simulation study and hybrid pharmacophore model development in human LTA4H inhibitor design.

Thangapandian S, John S, Arooj M, Lee KW.

PLoS One. 2012;7(4):e34593. doi: 10.1371/journal.pone.0034593. Epub 2012 Apr 5.

14.

Effect of the leukotriene A4 hydrolase aminopeptidase augmentor 4-methoxydiphenylmethane in a pre-clinical model of pulmonary emphysema.

De Oliveira EO, Wang K, Kong HS, Kim S, Miessau M, Snelgrove RJ, Shim YM, Paige M.

Bioorg Med Chem Lett. 2011 Nov 15;21(22):6746-50. doi: 10.1016/j.bmcl.2011.09.048. Epub 2011 Sep 20.

15.

A glutathione peroxidase, intracellular peptidases and the TOR complexes regulate peptide transporter PEPT-1 in C. elegans.

Benner J, Daniel H, Spanier B.

PLoS One. 2011;6(9):e25624. doi: 10.1371/journal.pone.0025624. Epub 2011 Sep 28.

16.

Probing conformational states of glutaryl-CoA dehydrogenase by fragment screening.

Begley DW, Davies DR, Hartley RC, Hewitt SN, Rychel AL, Myler PJ, Van Voorhis WC, Staker BL, Stewart LJ.

Acta Crystallogr Sect F Struct Biol Cryst Commun. 2011 Sep 1;67(Pt 9):1060-9. doi: 10.1107/S1744309111014436. Epub 2011 Aug 13.

17.

An ensemble of structures of Burkholderia pseudomallei 2,3-bisphosphoglycerate-dependent phosphoglycerate mutase.

Davies DR, Staker BL, Abendroth JA, Edwards TE, Hartley R, Leonard J, Kim H, Rychel AL, Hewitt SN, Myler PJ, Stewart LJ.

Acta Crystallogr Sect F Struct Biol Cryst Commun. 2011 Sep 1;67(Pt 9):1044-50. doi: 10.1107/S1744309111030405. Epub 2011 Aug 13.

18.

Structural genomics of infectious disease drug targets: the SSGCID.

Stacy R, Begley DW, Phan I, Staker BL, Van Voorhis WC, Varani G, Buchko GW, Stewart LJ, Myler PJ.

Acta Crystallogr Sect F Struct Biol Cryst Commun. 2011 Sep 1;67(Pt 9):979-84. doi: 10.1107/S1744309111029204. Epub 2011 Aug 13.

19.

Fragment screening of infectious disease targets in a structural genomics environment.

Begley DW, Davies DR, Hartley RC, Edwards TE, Staker BL, Van Voorhis WC, Myler PJ, Stewart LJ.

Methods Enzymol. 2011;493:533-56. doi: 10.1016/B978-0-12-381274-2.00021-2.

20.

Leveraging structure determination with fragment screening for infectious disease drug targets: MECP synthase from Burkholderia pseudomallei.

Begley DW, Hartley RC, Davies DR, Edwards TE, Leonard JT, Abendroth J, Burris CA, Bhandari J, Myler PJ, Staker BL, Stewart LJ.

J Struct Funct Genomics. 2011 Jul;12(2):63-76. doi: 10.1007/s10969-011-9102-6. Epub 2011 Feb 26.

Supplemental Content

Support Center